Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 11/20 | 0.64 |
| ▸ | BRD4 | O60885 | 4/20 | 0.63 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.54 |
| ▸ | MAP3K11 | Q16584 | 3/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.51 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.49 |
| ▸ | FEN1 | P39748 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15542823 | 0.87 | MAPK1 (0.70) | MAPK1BRD4RIPK1MAP3K11 | |
| SCHEMBL28513565 | 0.80 | MAPK1 (0.53) | MAPK1BRD4RIPK1 | |
| SCHEMBL6852771 | 0.78 | MAPK1 (0.72) | MAPK1RIPK1ALOX5APFEN1 | |
| SCHEMBL18136855 | 0.78 | MAPK1 (0.64) | MAPK1RIPK1ALOX5APFEN1 | |
| SCHEMBL720887 | 0.77 | BRD4 (1.00) | BRD4RIPK1MAP3K11LRRK2ALOX5AP | |
| SCHEMBL29086750 | 0.76 | MAPK1 (0.52) | MAPK1BRD4RIPK1MAP3K11LRRK2 | |
| SCHEMBL28513876 | 0.76 | MAPK1 (0.55) | MAPK1RIPK1 | |
| SCHEMBL29109163 | 0.75 | BRD4 (1.00) | BRD4MAP3K11LRRK2 | |
| SCHEMBL30663474 | 0.75 | BRD4 (1.00) | BRD4MAP3K11LRRK2 | |
| SCHEMBL15271249 | 0.73 | MAP3K11 (0.56) | BRD4MAP3K11LRRK2CYP2C9SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101952295-B | Pyrrolopyrazine kinase inhibitors | HOFFMANN LA ROCHE | 2013-11-20 | — | — | CN | disclosed |
| EP-2245033-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| CN-101952295-A | Pyrrolopyrazine kinase inhibitors | HOFFMANN LA ROCHE | 2011-01-19 | — | — | CN | disclosed |
| EP-2245033-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| WO-2009106441-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106441-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | MAPK1 386/4885BRD4 546/4885RIPK1 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.